DAR-T™: Where “faster” meets “better”
Experience a 3-day manufacturing turnaround time for your autologous CAR-T product, featuring high potency and persistence, with younger and less exhausted phenotype cells compared to conventional CAR-T options
-1.png?width=2000&height=518&name=DART%20Graphic%20100824-1%20(Updated)-1.png "Resilience Approach")
Time matters in CAR-T manufacturing. Age does, too.
It’s well known that cutting vein-to-vein time is a critical hurdle in the success of autologous CAR-T cell therapies. But there’s a second hurdle lined up right behind the first: As a patient's cells mature during the manufacturing expansion process, they differentiate, which dilutes their therapeutic potential.
Fulfilling the potential of youth
DAR-T from Resilience trims a typical 7-to-14 day manufacturing process down to just 3 days – positioning you to dose CAR-T cells into patients precisely when they are most durable and effective in destroying tumors and disease-causing cells.
POTENCY
3-day CAR-T cells have more IFN-γ release and greater cytotoxic activity than conventional 7-14 day CAR-T cells, which may result in lower dosage requirements and improved therapeutic outcome
PERSISTENCE
3-day CAR-T cells demonstrate an enhanced response to environmental stressors that speaks to the fitness and prolonged persistency in a tumor environment than a conventional 7-14 day CAR-T cells
PHENOTYPE
3-day CAR-T cells preserve a younger and less exhausted phenotype, presenting highly as central memory T cells and (to a lesser degree) naïve T cells, which may lead to better persistence in vivo than a conventional 7-14 day CAR-T cells
THE DAR-T ADVANTAGE
If you are pursuing an autologous CAR-T cell therapy, you’re well-versed in the incredible promise it has – and the inherent pressures it brings with it. We are, too. So by entrusting Resilience to put DAR-T to work on your behalf, you put a CDMO partner at your side that can help you:
Get Therapies to Patients Faster
Powered by a 3-day manufacturing process, DAR-T offers a total turnaround time (TAT) of 2 weeks or less
Curtail Production Costs
A shorter manufacturing timeline with DAR-T translates into lower labor and material costs
Limit Exposures
Fewer manual steps involved with DAR-T leads to a lower risk of error and/or contamination
Reinforce Investor Confidence
DAR-T can help you treat more patients faster, positioning you to more clearly demonstrate your innovation’s potential
KEEP YOUR THERAPY MOVING WITH DAR-T
I want to learn more
To see specific research data on DAR-T’s advantages, download our process brief.
I’d like to get started
To see if DAR-T could be a good fit for your next project, kickstart the discussion here.
Complete support, delivered completely
We believe that when your science meets our platforms and expertise, amazing things can happen. That’s why we’ve invested in coast-to-coast, end-to-end capabilities that can allow you to keep your innovation in the hands of a single production partner from preclinical to clinical and commercial cGMP manufacturing. And it’s why we’ve designed specific offerings – including SnapLVV and Auto-T – to streamline your cell therapy’s journey from idea to patient relief.
AUTO-T
Capitalize on Auto-T for LVV-based autologous CAR-T and TCR-T cell therapies that’s already been featured in multiple INDs, with its process and analytics having successfully cleared regulatory review.
SNAPLVV™
SnapLVV could serve as an ideal companion to your DAR-T project, giving you access to an off-the-shelf lentivirus vector process that readies you for first-in-human studies without time-consuming de novo development.
.png "Group 9 (1)")
FAQS
What is the difference between DAR-T and Auto-T?
DAR-T is exclusively for CAR-T cell products, while Auto-T is designed for LVV-based autologous engineered cell therapies. Auto-T has a 7-day manufacturing turnaround time and for DAR-T, it’s 3 days.
How fast can DAR-T get me ready for the clinic?
The typical timeline to receive IND-enabling material is less than 12 months. We recognize that each cell therapy design is unique, though, so connect with us to discuss your innovation and we can provide a more accurate ready-for-clinic timeline.
Where is your work conducted?
All development, manufacturing, and testing/quality operations take place inside our 85,000 sq. ft. Center of Excellence for Cellular Immunotherapy located outside of Philadelphia, PA. This site has a rich history of cell therapy expertise and is ideally located in a region with a strong cell therapy workforce.
How can Resilience achieve a 3-day manufacturing time?
Due to the greater activity of the naïve & central memory CAR-T cells used in DAR-T, the therapeutic dose needed for an effective therapy is smaller than that required for a traditional CAR-T cell therapy.
